VRAX
Closed
Virax Biolabs Group Limited Ordinary Shares
3.51
-0.52 (-12.90%)
Last Update: 06 Sep 2024 23:28:00
Yesterday: 4.03
Day's Range: 3.51 - 4.2613
Send
sign up or login to leave a comment!
When Written:
0.6124
Virax Biolabs Group Limited is a biotechnology company that develops and commercializes innovative diagnostic and therapeutic products for the treatment of viral infections, including COVID-19. The company's products are based on its proprietary technology platform that enables the rapid identification and development of targeted therapies for viral diseases.
The company's ordinary shares are listed on the Australian Securities Exchange (ASX) under the ticker symbol VBL. As of August 2021, the company had a market capitalization of approximately AUD 70 million.
Virax Biolabs Group Limited is headquartered in Sydney, Australia, and has operations in the United States, Europe, and Asia. The company's management team includes experienced executives with a track record of success in the biotechnology industry.
The company's flagship product is VIR-202, a novel monoclonal antibody therapy for the treatment of COVID-19. The company has also developed a range of diagnostic tests for viral infections, including COVID-19, influenza, and HIV.
Virax Biolabs Group Limited is focused on developing innovative solutions to address the global threat of viral diseases and is committed to improving the health and well-being of people around the world.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's ordinary shares are listed on the Australian Securities Exchange (ASX) under the ticker symbol VBL. As of August 2021, the company had a market capitalization of approximately AUD 70 million.
Virax Biolabs Group Limited is headquartered in Sydney, Australia, and has operations in the United States, Europe, and Asia. The company's management team includes experienced executives with a track record of success in the biotechnology industry.
The company's flagship product is VIR-202, a novel monoclonal antibody therapy for the treatment of COVID-19. The company has also developed a range of diagnostic tests for viral infections, including COVID-19, influenza, and HIV.
Virax Biolabs Group Limited is focused on developing innovative solutions to address the global threat of viral diseases and is committed to improving the health and well-being of people around the world.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!